Clinical trial · Interventional
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
NCT06910670CI-TRIAL-00119071active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetics Advisor Decision Aid | Other | — | UNRESOLVED |
| Standard developed materials | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention: Genetics Advisor Online Tool
- description
- The Intervention group will receive the expanded Genetics Advisor decision aid.
- interventionNames
- Other: Genetics Advisor Decision Aid
- type
- ACTIVE_COMPARATOR
- label
- Control: Standard developed materials
- description
- The control group will receive a description of each type of genomic sequencing result they could receive using the standard informed consent process for the return-of-results protocol.
Primary outcomes (1)
- measure
- Change in self-efficacy about genomic test results
- timeFrame
- Baseline, after viewing assigned materials (day 1), and 3-months after enrollment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Eligibility Criteria: * Enrolled in the WU-PE-CGS study (IRB#202106129); that eligibility entails: * Diagnosis of cholangiocarcinoma * Diagnosis of multiple myeloma, must be African American * Diagnosis of colorectal cancer, must be African American and age 65 or older at time of diagnosis * At least 18 years old. * Able to understand an IRB-approved informed consent document and agree to participation * Have access to a personal computer, tablet or mobile device
References
Publications (0)
Data not yet available
No reference posted for this study.